Detalhe da pesquisa
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38631003
2.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist
; 29(2): 142-150, 2024 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37589219
3.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33577729
4.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34407342
5.
Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Curr Oncol Rep
; 26(4): 307-317, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38381366
6.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 24(8): 881-891, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37451291
7.
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Int J Cancer
; 153(6): 1241-1250, 2023 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37294085
8.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36573926
9.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36055304
10.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35029306
11.
Clinical features and oncological outcomes of primary female urethral cancer.
J Surg Oncol
; 125(5): 907-915, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35050502
12.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33991512
13.
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
BJU Int
; 128(5): 607-614, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33909949
14.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32971005
15.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31753727
16.
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
Br J Cancer
; 122(11): 1630-1637, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32238921
17.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31079938
18.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Artigo
Inglês
| MEDLINE | ID: mdl-28212060
19.
FGFR1 is associated with c-MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti-angiogenic therapy.
Histopathology
; 76(6): 838-851, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-31990416
20.
Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Eur Radiol
; 30(10): 5392-5403, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32394281